Entries by visicort_admin

VISICORT coordinator Prof. Matt Griffin visits leading US medical centre Mayo Clinic to discuss EU-funded mesenchymal stromal cell projects

Prof. Matt Griffin of the National University of Ireland Galway visited the Division of Nephrology and Hypertension and the William J von Liebig Transplant Center at Mayo Clinic, Rochester, Minnesota between September 27th and October 2nd 2019. While there, he engaged with clinical investigators involved in a range of Mayo Clinic research initiatives in regenerative medicine and transplantation. He gave […]

VISICORT PIs chair sessions at EVER 2019 in Nice

The European Association for Vision and Eye Research (EVER) 2019 meeting was held in Nice, France on October 17th- 19th. VISICORT PIs Prof Uwe Pleyer of Charité and Prof Jesper Hjortdal of Aarhus University Hospital were in attendance and very active. VISICORT was represented and acknowledged in several sessions. On Saturday, October 19th Prof Pleyer […]

VISICORT meeting with Epimune Diagnostics

Epimune (www.epimune-dx.com) and the VISICORT Consortium are interested in entering into a collaboration in the field of diagnosis and monitoring of corneal transplant recipients using epigenetic immune cell quantification. The goal of the collaboration is the exploration of epigenetic immune cell quantification to monitor patients after corneal transplantation and to detect (and potentially predict) adverse […]

VISICORT clinical trial listed on Charité’s BeCAT website

“An outstanding project within the VISICORT consortium is a Phase 1B clinical trial testing the safety and feasibility of intravenously administered allogeneic mesenchymal stromal cells (allo-MSC) as an immunotherapy for patients at high risk of keratoplasty. Following recent regulatory and ethical approval for the first clinical study on the risk therapy for cell therapy in […]

VISICORT publication in the Official Journal of the Transplantation Society

Congratulations to the team! VISICORT PIs and researchers spanning the consortium have recently released a new paper in the Official Journal of the Transplantation Society. The paper entitled: “High-Risk Corneal Transplantation, Recent Developments and Future Possibilities” was released 22 August 2019. Authors are W. John Armitage, PhD; Christine Goodchild, MD; Matthew D. Griffin, DMed; David […]

VISICORT PI Ritter, NUI Galway joins Therapeutics Delivery COST Action

Prof. Thomas Ritter of NUI Galway has joined “DARTER”- a COST Action CA 17103- Delivery of Antisense RNA Therapeutics. Here, Thomas aims to broaden his research network and to forge new partnerships to explore novel, RNA-based therapies for the treatment of ocular defects and the modulation of corneal transplant rejection. DARTER has three research objectives- […]

VISICORT PIs present at Societas Ophthalmologica Europæa

On June 16, 2019, Prof. Jesper Hjortdal, of the Aarhus University Hospital gave a presentation at the SOE (Societas Ophthalmologica Europæa, or European Society of Ophthalmology) on “Adverse immune signatures after corneal transplantation” based on the preliminary findings in the VISICORT study. This year the SOE held its bi-annual meeting in Nice, France. The symposium […]

Interview 2: Proteomics Specialist Lisa Imrie, U of Edinburgh offers a research career snapshot

In the 5 years since its launch, VISICORT has gathered a unique collection of biological samples from corneal transplant recipients across 5 European countries. We are especially motivated to ensure that the generosity of these patients has a legacy of new research that continues to grow beyond the life-time of the project itself. Lisa’s exciting […]